Mutual of America Capital Management LLC Acquires 160 Shares of Agilent Technologies, Inc. (NYSE:A)

Mutual of America Capital Management LLC increased its holdings in Agilent Technologies, Inc. (NYSE:A) by 0.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,306 shares of the medical research company’s stock after acquiring an additional 160 shares during the period. Mutual of America Capital Management LLC’s holdings in Agilent Technologies were worth $7,469,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in A. Massachusetts Financial Services Co. MA grew its stake in shares of Agilent Technologies by 5.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after acquiring an additional 809,149 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Agilent Technologies by 13.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock worth $1,242,956,000 after purchasing an additional 1,042,926 shares in the last quarter. Van ECK Associates Corp increased its stake in Agilent Technologies by 6.6% in the 3rd quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock valued at $442,011,000 after buying an additional 183,716 shares during the last quarter. Impax Asset Management Group plc lifted its position in shares of Agilent Technologies by 8.2% during the 3rd quarter. Impax Asset Management Group plc now owns 2,667,616 shares of the medical research company’s stock worth $396,088,000 after buying an additional 203,234 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of Agilent Technologies by 2.3% during the 2nd quarter. Victory Capital Management Inc. now owns 2,386,039 shares of the medical research company’s stock worth $309,302,000 after buying an additional 52,550 shares in the last quarter.

Agilent Technologies Trading Down 0.1 %

NYSE:A opened at $126.92 on Tuesday. The company has a market cap of $36.47 billion, a P/E ratio of 26.33, a P/E/G ratio of 5.59 and a beta of 1.07. Agilent Technologies, Inc. has a 1 year low of $112.39 and a 1 year high of $155.35. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. The stock’s fifty day moving average price is $138.50 and its two-hundred day moving average price is $137.92.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter last year, the company earned $1.43 EPS. The firm’s revenue was down 5.6% compared to the same quarter last year. As a group, analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were paid a $0.236 dividend. This represents a $0.94 annualized dividend and a yield of 0.74%. The ex-dividend date was Tuesday, October 1st. Agilent Technologies’s dividend payout ratio is presently 19.50%.

Insider Activity

In related news, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. This trade represents a 19.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the sale, the chief executive officer now owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. The trade was a 7.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,995 shares of company stock worth $1,739,510 in the last three months.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Evercore ISI increased their price target on Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Citigroup lifted their target price on Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Barclays increased their price target on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “underweight” rating in a research report on Tuesday, October 15th. Wells Fargo & Company began coverage on shares of Agilent Technologies in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price objective on the stock. Finally, Bank of America increased their target price on shares of Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.36.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.